Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer.

Autor: Lee TW; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand., Lai A; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand.; Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland 1023, New Zealand., Harms JK; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand., Singleton DC; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand., Dickson BD; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand., Macann AMJ; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand.; Department of Radiation Oncology, Auckland City Hospital, Auckland 1023, New Zealand., Hay MP; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand., Jamieson SMF; Auckland Cancer Society Research Centre, University of Auckland, Auckland 1023, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand.; Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland 1023, New Zealand.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 Dec 12; Vol. 12 (12). Date of Electronic Publication: 2020 Dec 12.
DOI: 10.3390/cancers12123743
Abstrakt: Patient survival from head and neck squamous cell carcinoma (HNSCC), the seventh most common cause of cancer, has not markedly improved in recent years despite the approval of targeted therapies and immunotherapy agents. Precision medicine approaches that seek to individualise therapy through the use of predictive biomarkers and stratification strategies offer opportunities to improve therapeutic success in HNSCC. To enable precision medicine of HNSCC, an understanding of the microenvironment that influences tumour growth and response to therapy is required alongside research tools that recapitulate the features of human tumours. In this review, we highlight the importance of the tumour microenvironment in HNSCC, with a focus on tumour hypoxia, and discuss the fidelity of patient-derived xenograft and organoids for modelling human HNSCC and response to therapy. We describe the benefits of patient-derived models over alternative preclinical models and their limitations in clinical relevance and how these impact their utility in precision medicine in HNSCC for the discovery of new therapeutic agents, as well as predictive biomarkers to identify patients' most likely to respond to therapy.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje